Study of FID-022 for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new drug called FID-022 for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those who could benefit from irinotecan, a common chemotherapy drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor cancer that has spread, cannot be removed, or has come back, and standard treatments are not working or irinotecan is a good option.
- You have not had more than 3 types of chemotherapy for your advanced cancer (unless the study team says okay).
- You do not have active brain tumors that are causing symptoms (small, stable brain spots may be okay).
- You are not allergic to irinotecan or similar drugs.
- You are willing to use two forms of birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This study tests whether a new drug called a FAK inhibitor can help patients with advanced cancers that have spread or stopped responding to standard treatments. FAK is a protein that helps cancer cells grow, and blocking it may slow tumor growth.
This trial tests an experimental drug called FP008, which may help the immune system fight advanced solid tumors. It is for people whose cancer has continued to grow despite standard treatments or who cannot tolerate them.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
This trial tests a new study drug called FID-022 for people with pancreatic cancer. It is a first-in-human study, meaning it is the first time this drug is being tested in people, and researchers want to see if it is safe and how it works.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.